441798-33-0 | N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide

Availability
Typically In Stock

Description

• Catalog Number: AB52274
• Chemical Name: N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide
• CAS Number: 441798-33-0
• Molecular Formula: C19H20Br2N6O4S
• Molecular Weight: 588.2729
• MDL Number: MFCD17167076
• SMILES: CCCNS(=O)(=O)Nc1ncnc(c1c1ccc(cc1)Br)OCCOc1ncc(cn1)Br

Computed Properties

• Complexity: 642
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 32
• Hydrogen Bond Acceptor Count: 10
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 11
• XLogP3: 3.7

Literature

• From the Cover: MechanisticInsights in Cytotoxic and Cholestatic Potential of the Endothelial Receptor Antagonists Using HepaRG Cells.

  Toxicological sciences : an official journal of the Society of Toxicology 20170601

• Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension.

  Reproductive toxicology (Elmsford, N.Y.) 20150815

• Pathways in pulmonary arterial hypertension: the future is here.

  European respiratory review : an official journal of the European Respiratory Society 20121201

• Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist.

  Life sciences 20121015

• The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.

  Journal of medicinal chemistry 20120913

• Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.

  The AAPS journal 20120301

• Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.

  PloS one 20120101

• Macitentan: entry-into-humans study with a new endothelin receptor antagonist.

  European journal of clinical pharmacology 20111001

• Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer.

  Neoplasia (New York, N.Y.) 20110201

• Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis.

  Current opinion in investigational drugs (London, England : 2000) 20100901

• Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20091105

• Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.

  The Journal of pharmacology and experimental therapeutics 20081201